glp-1 side effect class action in michigan attorney James Boyd, a lawyer at Siskinds LLP, shares insights on a proposed class action targeting drugs Ozempic

For women with robust glutathione levels and healthy detoxification pathways, occasional use at recommended doses appears to pose minimal risk

The growing popularity of GLP-1 receptor agonists will have a significant impact on the pharmaceutical sector with commercial and IP considerations becoming just as important as clinical efficacy

Schizophrenia Dopamine-serotonin imbalance, cognitive dysfunction

Areas Without Adequate Human Evidence Long-term cardiovascular safety Long-term neurological safety Endocrine effects beyond selected hormone measurements Effects on glucose regulation in people Immune responses Allergic reactions Genotoxicity Carcinogenicity Effects in people with cancer or precancerous disease Reproductive and developmental toxicity Pregnancy safety Breastfeeding safety Paediatric exposure Medicine interactions Interaction with hormone or sleep treatments Repeated exposure over months or years Product-Quality Risks Incorrect amino-acid sequence Glu and Asp residue-order errors Wrong terminal groups Incorrect free-base or acetate designation Incorrect peptide quantity Deletion-sequence impurities Incomplete deprotection Residual synthesis reagents Residual solvents Peptide aggregates Degradation during transport or storage Unverified microbiological quality Unverified bacterial-endotoxin control Certificates unrelated to the supplied batch No reports does not mean no risk FDAs adverse-event database search found no Epitalon reports through December 2025

A 2026 systematic review and meta-analysis of randomized controlled trials confirmed that GLP-1 receptor agonists produce clinically meaningful weight loss across diverse patient populations (Ahmad et al., 2026, PMID: 41824845)